Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)
Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294
Factory : Plot No. B-4 & 5, Industrial Focal Point, Derabassi, Punjab (India)
Ph. 01762-281278, 79. CIN NO. U74999CH1993PLC033428

Date: 12th December, 2017

The President,
Corporate Relationship Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

BSE Scrip Code: 524652

The Vice President,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No.C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

NSE Symbol: INDSWFTLTD

Ref: Company Name: Ind-Swift Limited

Sub: Disclosures under Regulations 10(6) and 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011

Dear Sir,

This is to inform the Exchange that pursuant to the Composite scheme of amalgamation inter-alia of AKJ Portfolios Pvt Ltd., GM Portfolios Pvt. Ltd., NRM Portfolios Pvt. Ltd., SRM Portfolios Pvt. Ltd., VKM Portfolios Pvt. Ltd. and VRM Portfoilos Pvt. Ltd. (**"Transferor Companies"**) with Essix Biosciences Limited (**"Transferee Company"**) as approved by Hon'ble National Company Law Tribunal, Chandigarh Bench vide its order CP No. 153/2016 dated 08.11.2017, received on 06.12.2017, the transferor Companies have been amalgamated with the transferee Company with effect from 09.12.2017. Pursuant to the sanctioned scheme, the entire shareholding of Ind-Swift Limited held by the Transferor Companies stands transferred to the transferee Company.

In this regard, please find enclosed the following:

(i) Report under Regulation 10(6) of the SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011

(ii) Disclosure under Regulation 29(2) of the SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011

You are requested to kindly take the same on record.


For **Essix Biosciences Limited**

Director

Cc:
The Compliance Officer
Ind-Swift Limited
781, INDUSTRIAL AREA,
PHASE-II, CHANDIGARH-160002

Format for Disclosures under Regulation 10(6) – Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Ind-Swift Limited	
2.	Name of the acquirer(s)	Essix Biosciences Limited	
3.	Name of the stock exchange where shares of the TC are listed	BSE Ltd. and National Stock Exchange of India Limited	
4.	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares.	Pursuant to a composite scheme of amalgamation of AKJ Portfolios Pvt Ltd., GM Portfolios Pvt. Ltd., NRM Portfolios Pvt. Ltd., SRM Portfolios Pvt. Ltd., VKM Portfolios Pvt. Ltd., VRM Portfoilos Pvt. Ltd., Integral Buildcon Private Limited and Consummate Pharmaceuticals Pvt. Ltd. ("**Transferor Companies**") with Essix Biosciences Limited ("**Transferee Company**") as approved by Hon'ble National Company Law Tribunal, Chandigarh Bench vide its order CP No. 153/2016 dated 08.11.2017, received on 06.12.2017, the transferor Companies stand amalgamated with the transferee Company with effect from 09.12.2017, and consequently, all the assets and liabilities of the Transferor Companies including their shareholding in Ind-Swift Limited (i.e. the target Company) stand transferred to the transferee Company. Accordingly, 7817712 equity shares of Ind-Swift Limited constituting 14.45% of the paid up share capital of Ind-Swift Limited as held by transferor Companies stand transferred to the Transferee Company (subject to completion of requisite procedural formalities) in addition to existing shareholding of transferee Company in Ind-Swift Ltd of 9215721 equity shares. The key rationale for the amalgamation envisaged under the scheme is that the amalgamation shall provide the Transferee Company a strong and focused base to undertake the business more advantageously. The scheme will also result in the consolidation of the Promoter shareholding in Ind-Swift Limited and the consolidation of group Companies.	
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10(1)(d)(iii) of SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011. (SAST Regulations)	
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, – Whether disclosure was made and whether it was made within the timeline specified under the regulations. – Date of filing with the stock exchange.	The disclosure under Regulation 10(5) of the SAST Regulations is not required to be made in the present case. N.A. N.A.	
7.	Details of acquisition	Disclosures made/required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made



	a. Name of the transferor / seller	N.A.		N.A.	
	b. Date of acquisition	N.A.		N.A.	
	c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	N.A.		N.A.	
	d. Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	N.A.		N.A.	
	e. Price at which shares are proposed to be acquired / actually acquired	N.A.		N.A.	
8.	Shareholding details	**Pre-Transaction**		**Post-Transaction**	
		No. of shares held	**% w.r.t. to total share capital of TC**	**No. of shares held**	**% w.r.t. to total share capital of TC**
	- Each ~~Acquirer~~ / Transferee(*) Essix Biosciences Limited	9215721	17.01	17033433	31.45
	- Each ~~Seller~~ / Transferor AKJ Portfolios Pvt. Limited NRM Portfolios Pvt. Limited GM Portfolios Pvt. Limited VKM Portfolios Pvt. Limited VRM Portfolios Pvt. Limited SRM Portfolios Pvt. Limited	 675000 675000 2675000 650000 1303570 1839142	 1.25 1.25 4.94 1.20 2.41 3.40	 - - - - - -	 - - - - - -

For ESSIX BIOSCIENCES LIMITED

V R MEHTA
DIRECTOR
DIN: 00010756

Place: Chandigarh
Date: 12.12.2017

Note:

- (*) Shareholding of each entity shall be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.